{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:30:51Z","timestamp":1787592651879,"version":"build-2736575974"},"reference-count":55,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,9,18]]},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.2967\/jnumed.125.270215","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:25:14Z","timestamp":1761229514000},"page":"1948-1955","source":"Crossref","is-referenced-by-count":4,"title":["Extravasation of Therapeutic Radiopharmaceuticals: A Systematic Review and Management Proposal"],"prefix":"10.2967","volume":"66","author":[{"given":"Juanito","family":"Gebruers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Terwinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Graven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Everaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Baete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloefar","family":"Ahmadi Bidakhvidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2026030506250587000_66.12.1948.1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3352\/jeehp.2020.17.21","article-title":"Guidelines for the management of extravasation","volume":"17","author":"Kim","year":"2020","journal-title":"J Educ Eval Health Prof."},{"key":"2026030506250587000_66.12.1948.2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.semnuclmed.2021.11.006","article-title":"Radiation safety and accidental radiation exposures in nuclear medicine","volume":"52","author":"Marengo","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2026030506250587000_66.12.1948.3","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s00259-017-3675-7","article-title":"Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review","volume":"44","author":"van der Pol","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250587000_66.12.1948.4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/cancers14010129","article-title":"Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications, and optimization strategies","volume":"14","author":"Ahmadi Bidakhvidi","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026030506250587000_66.12.1948.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2026030506250587000_66.12.1948.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2026030506250587000_66.12.1948.7","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated gastroenteropancreatic neuroendocrine tumors (NETTER-2): an open-label, randomized, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2026030506250587000_66.12.1948.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026030506250587000_66.12.1948.9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250587000_66.12.1948.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0372-y"},{"key":"2026030506250587000_66.12.1948.11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00259-018-3947-x","article-title":"EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides","volume":"45","author":"Handkiewicz-Junak","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250587000_66.12.1948.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05541-7"},{"key":"2026030506250587000_66.12.1948.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2026030506250587000_66.12.1948.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6"},{"key":"2026030506250587000_66.12.1948.15","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","article-title":"Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0","volume":"51","author":"Albert","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250587000_66.12.1948.16","unstructured":"Pereira LR . Patient Care. In: Terwinghe C Santos A Pietrzak A , eds. Radionuclide therapy Management: A Technologists Guide. https:\/\/eanm.org\/wp-content\/uploads\/2024\/06\/EANM22_TechGuide.pdf. Accessed October 6, 2025."},{"key":"2026030506250587000_66.12.1948.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2026030506250587000_66.12.1948.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2017.09.004"},{"key":"2026030506250587000_66.12.1948.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1950.82910410013009c"},{"key":"2026030506250587000_66.12.1948.20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00296-008-0571-2","article-title":"Treatment of skin necrosis after radiation synovectomy with yttrium-90: a case report","volume":"28","author":"Oztrk","year":"2008","journal-title":"Rheumatol Int."},{"key":"2026030506250587000_66.12.1948.21","doi-asserted-by":"publisher","DOI":"10.1097\/00000637-199405000-00019"},{"key":"2026030506250587000_66.12.1948.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.8.861"},{"key":"2026030506250587000_66.12.1948.23","first-page":"58","article-title":"Cutaneous radiation necrosis as a complication of yttrium-90 synovectomy","volume":"8","author":"Sojan","year":"2005","journal-title":"Hell J Nucl Med."},{"key":"2026030506250587000_66.12.1948.24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00003086-199103000-00015","article-title":"Radiocolloids in the management of hemophilic arthropathy in children and adolescents","volume":"264","author":"Erken","year":"1991","journal-title":"Clin Orthop Relat Res."},{"key":"2026030506250587000_66.12.1948.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0295-2"},{"key":"2026030506250587000_66.12.1948.26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5114\/reum.2018.76905","article-title":"Beta burns following radionuclide synovectomy","volume":"56","author":"Chojnowski","year":"2018","journal-title":"Reumatologia."},{"key":"2026030506250587000_66.12.1948.27","first-page":"S205","article-title":"Extravasation of 90Y-DOTATOC: case report and discussion of potential effects, remedies and precautions in PRRT","volume":"39","author":"Terwinghe","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250587000_66.12.1948.28","first-page":"S82","article-title":"Preventive measures and management of radiopharmaceutical extravasation with [177Lu]Lu-DOTATATE","volume":"47","author":"Eftychiou","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250587000_66.12.1948.29","first-page":"S844","article-title":"Management of extravasation of lutetium-177 DOTATOC","volume":"46","author":"Bekker","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250587000_66.12.1948.30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-021-00378-3","article-title":"Tissue dose estimation after extravasation of 177Lu-DOTATATE","volume":"8","author":"Tylski","year":"2021","journal-title":"EJNMMI Phys."},{"key":"2026030506250587000_66.12.1948.31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/RLU.0000000000003452","article-title":"Effective management of 177Lu-DOTA0-Tyr3-octreotate extravasation","volume":"46","author":"Maucherat","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2026030506250587000_66.12.1948.32","first-page":"4076","article-title":"Lu-177 lutetium Dotatate infusion safety: infiltration or extravasation [abstract]?","volume":"63","author":"Valencia","year":"2022","journal-title":"J Nucl Med."},{"key":"2026030506250587000_66.12.1948.33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/HP.0000000000001558","article-title":"Lutetium-177 radiopharmaceutical therapy extravasation: lessons learned","volume":"123","author":"Berry","year":"2022","journal-title":"Health Phys."},{"key":"2026030506250587000_66.12.1948.34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/RLU.0000000000005137","article-title":"Extravasation after [177Lu]Lu-HA-DOTATATE therapy","volume":"49","author":"de Vries-Huizing","year":"2024","journal-title":"Clin Nucl Med."},{"key":"2026030506250587000_66.12.1948.35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13550-020-00658-6","article-title":"Extravasation of [177Lu]Lu-DOTATOC: case report and discussion","volume":"10","author":"Arveschoug","year":"2020","journal-title":"EJNMMI Res."},{"key":"2026030506250587000_66.12.1948.36","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.21.101"},{"key":"2026030506250587000_66.12.1948.37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1188\/08.CJON.275-278","article-title":"Extravasation of yttrium-90 ibritumomab tiuxetan: a case study","volume":"12","author":"Siebeneck","year":"2008","journal-title":"Clin J Oncol Nurs."},{"key":"2026030506250587000_66.12.1948.38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.anplas.2017.11.007","article-title":"Complex upper arm reconstruction using an antero-lateral thigh free flap after an extravasation of yttrium-90-ibritumomab tiuxetan: a case report and literature review","volume":"63","author":"Baus","year":"2018","journal-title":"Ann Chir Plast Esthet."},{"key":"2026030506250587000_66.12.1948.39","first-page":"78","article-title":"Focal cutaneous squamous cell carcinoma following radium-223 extravasation","volume":"30","author":"Benjegerdes","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)."},{"key":"2026030506250587000_66.12.1948.40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/1874471012666190927115331","article-title":"Analysis of unusual adverse effects after radium-223 dichloride administration","volume":"13","author":"Frantellizzi","year":"2020","journal-title":"Curr Radiopharm."},{"key":"2026030506250587000_66.12.1948.41","first-page":"56","article-title":"Subcutaneous extravasation of Sr-89: usefulness of bremsstrahlung imaging in confirming Sr-89 extravasation and in the decision-making for the choice of treatment strategies for local radiation injuries","volume":"1","author":"Kawabe","year":"2013","journal-title":"Asia Ocean J Nucl Med Biol."},{"key":"2026030506250587000_66.12.1948.42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/RLU.0000000000003049","article-title":"Monitoring and handling of 89Sr injection site extravasation in a patient with breast cancer","volume":"45","author":"Tang","year":"2020","journal-title":"Clin Nucl Med."},{"key":"2026030506250587000_66.12.1948.43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/RLU.0000000000001715","article-title":"Possible treatment approach to an extravasation of 177Lu-PSMA-617","volume":"42","author":"Schlenkhoff","year":"2017","journal-title":"Clin Nucl Med."},{"key":"2026030506250587000_66.12.1948.44","doi-asserted-by":"crossref","first-page":"N10","DOI":"10.1055\/s-0038-1641692","article-title":"Successful handling of an accidental extravasation of 177Lu-PSMA-617 in the treatment of advanced prostate cancer","volume":"57","author":"Jptner","year":"2018","journal-title":"Nuklearmedizin."},{"key":"2026030506250587000_66.12.1948.45","first-page":"87","article-title":"Dosimetry of aqueous 32P after soft-tissue infiltration following attempted intravenous administration","volume":"52","author":"Minsky","year":"1987","journal-title":"Health Phys."},{"key":"2026030506250587000_66.12.1948.46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.083725"},{"key":"2026030506250587000_66.12.1948.47","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.177.1.1770003"},{"key":"2026030506250587000_66.12.1948.48","doi-asserted-by":"publisher","DOI":"10.1038\/nrg758"},{"key":"2026030506250587000_66.12.1948.49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265891"},{"key":"2026030506250587000_66.12.1948.50","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/tomography8010029","article-title":"Cutaneous management after extravasation of high-concentrated amino acid solution administered for renal protection in PRRT","volume":"8","author":"Sakulpisuti","year":"2022","journal-title":"Tomography."},{"key":"2026030506250587000_66.12.1948.51","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5603\/NMR.a2022.0030","article-title":"Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE","volume":"25","author":"Divband","year":"2022","journal-title":"Nucl Med Rev Cent East Eur."},{"key":"2026030506250587000_66.12.1948.52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269411"},{"key":"2026030506250587000_66.12.1948.53","unstructured":"Article 63: accidental and unintended exposures. Council directive 2013\/59\/EURATOM. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2014:013:0001:0073:EN:PDF Published January 17, 2014. Accessed October 6, 2025."},{"key":"2026030506250587000_66.12.1948.54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/HP.0000000000001600","article-title":"Practical tools for patient-specific characterization and dosimetry of radiopharmaceutical extravasation","volume":"123","author":"Wilson","year":"2022","journal-title":"Health Phys."},{"key":"2026030506250587000_66.12.1948.55","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264225"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:19:18Z","timestamp":1785269958000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":55,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.2967\/jnumed.125.270215"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270215","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}